Media room

Research finance in the professional conversation

The Development Finance Review

Fictional research-finance journal

The closeout budget was part of accepting the result

I discuss a portfolio decision after a programme failed to support its proposed expansion. The account retains USD31 million of past expenditure, USD16 million of proposed next-year work and USD2.6 million of closeout and transition. It includes the twenty-two affected colleagues and the responsibilities that remained. The argument concerns forward resource judgement, with scientific and medical conclusions left to qualified leaders rather than inferred from the budget decision.

Research Capital Letters

Fictional private-company funding essay series

A cash balance needs a development calendar

I compare an eighteen-month base plan using USD78 million with a downside using USD96 million against USD92 million of opening cash. The discussion examines why a historical spending average cannot describe every future commitment. A later USD60 million gross equity round is shown with USD3 million of fees and the dilution accepted. The transaction improves funding capacity without establishing a programme's success or the total capital eventually required.

The Trial Cost Ledger

Fictional research-operations interview publication

The quiet ledger and the busy research team

I examine USD3.8 million of incurred research work absent from an initial period-end estimate. The correction is distinguished from new spending authority and an immediate cash payment. The interview follows the operating confirmations and supplier evidence that support a more complete account. It also separates a later improvement in estimate-to-invoice differences from any claim that the underlying research became cheaper or that every company estimate was thereby validated.

Portfolio Evidence Quarterly

Fictional development-governance review

What the smaller supplier commitment actually purchased

I describe a USD1.4 million reservation and preparation arrangement in place of an immediate USD9.6 million production commitment. The account explains the work and time-limited access purchased, the residual schedule risk and the later decision still required. It does not label the USD8.2 million uncommitted difference a saving. The discussion asks whether a funded stage produces information and practical readiness before the organisation must decide on a larger obligation.

The Biopharma Funding Notebook

Fictional collaboration-economics publication

Potential consideration is not current spending power

I follow a collaboration with USD12 million upfront and up to USD48 million dependent on later development events. The contribution preserves the commercial opportunity while separating received cash, conditional scenarios and the accounting assessment. It also discusses USD3.1 million allocated to near-term collaboration work without treating the remaining receipt as profit. The central question is whether the portfolio's unconditional plan remains understandable before any future payment condition has been satisfied.

Media biography

Miriam Valcera is a fictional CFO based in the United States whose work concerns capital allocation in clinical-stage therapeutics. She leads finance at Velmara Therapeutics, a privately held Boston company employing 280 people. Its four clinical and two preclinical programmes have not produced an approved or marketed medicine. The company's 2025 USD18 million revenue came from collaboration activity, not product sales.

Valcera began in research-contract accounting in July 1990 after an accounting degree. Her subsequent appointments covered clinical finance, development planning and financial control before she became CFO in May 2018. She leads twenty-one colleagues through four direct reports and presents to directors without holding a board appointment. Her demonstration cases explore responsible programme closure, financing timetables, incurred research costs and conditional partnership payments. She is considering a first external board contribution, initially proposing twenty annual days subject to the actual calendar and relationship review. The media entries and speaking topics are fictional examples, with no implied clinical advice or verified public appearances.

Biographies

Approved text

Short speaker biography

Miriam Valcera is a fictional US therapeutics CFO who connects research choices with the capital and obligations behind them. She leads twenty-one finance colleagues at Velmara Therapeutics. Her proposed discussions examine programme closure, development cash scenarios and conditional partnership value, while keeping scientific and medical authority with appropriately qualified leaders.

Standard speaker biography

Miriam Valcera is a fictional finance leader at Velmara Therapeutics, a privately held clinical-stage company in Boston. Its 280 employees work across four clinical and two preclinical programmes, with no approved or marketed medicine. She became CFO in May 2018 after appointments in research-contract accounting, clinical finance and development planning.

Her demonstration cases examine the funded closure of a programme, an equity financing against a downside schedule, research-cost estimates and conditional collaboration receipts. She leads twenty-one finance colleagues and presents to the board without holding a directorship. Her proposed talks focus on resource judgement and oversight, not treatment advice or the scientific assessment of a medicine.

Extended speaker biography

Miriam Valcera is a fictional US pharmaceutical finance executive whose thirty-six-year career connects research activity with financial responsibility. She began in contract accounting at Sorevane Research in 1990, moved into clinical finance management and joined Velmara Therapeutics in 2004 to lead development planning. She became vice president of finance in April 2011 and chief financial officer in May 2018.

Velmara is a privately held Boston development company with 280 employees, four clinical programmes and two preclinical programmes. It has no approved or marketed medicine. Valcera leads twenty-one finance colleagues through four direct reports. The examples in her demonstration profile distinguish collaboration revenue from product sales, conditional consideration from received cash and financing success from research success. A programme-closure case includes the continuing obligations and consequences for colleagues, while the cash-planning account preserves both a base and a less favourable schedule.

She presents financial matters to the board and audit committee as management and holds no directorship. She is considering one first external board contribution with an initial twenty-day annual capacity proposal, subject to relationships, calendar and employer consent. Her speaking programme consists of proposed discussions using fictional evidence. It makes no claim of past appearances, clinical authority or access to study participation.

An invitation

Contact

I welcome a carefully scoped board or speaking conversation about research funding, portfolio choices and financial oversight. I have no current directorship and could consider one first external seat with twenty annual days initially available, subject to conflicts and employer consent. I do not provide clinical advice or access to study participation through this profile.

Open to

Board appointments
Speaking invitations

Write to Miriam

office@miriamvalcera.example